Answers are grounded in this paper and cite their sources.
BACKGROUND: Galectin 3 (G3) is a mediator of fibrosis and remodeling in heart failure. METHODS: Patients diagnosed with and treated for Acute Heart Failure Syndromes were prospectively enrolled in the Decision Making in Acute Decompensated Heart Failure multicenter trial. RESULTS: Patients with a higher G3 had a history of renal disease, a lower heart rate and acute kidney injury. They also tended to have a history of HF and 30-day adverse events compared with B-type natriuretic peptide. CONCLUSION: In Acute Heart Failure Syndromes, G3 levels do not provide prognostic value, but when used complementary to B-type natriuretic peptide, G3 is associated with renal dysfunction and may predict 30-day events.
No takes yet. Share an insight, caveat, or question.
Fermann et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: